Clinic
Ahpaffs,llc
Ahpaffs,llc was paid $14.19M by Medicaid between Sep 2019 and Dec 2024, across 90 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 66% of everything it billed.
33Billing provider infoAHPAFFS,LLC
PHILADELPHIA, PA 19133
PHILADELPHIA, PA 19133
33aNPI1275985814assigned 07/07/2016
33bProvider typeUrgent Care Clinic/Center
28Total paid$14.19M
24GClaims215,672
24DCodes billed90
24AFirst – last monthSep 2019 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Pennsylvania
Rank by total paid#5 of 68
Median peer was paid$914K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 407 | $39K | |
| 2020 | 14,187 | $742K | |
| 2021 | 48,036 | $3.33M | |
| 2022 | 62,405 | $3.61M | |
| 2023 | 48,123 | $3.49M | |
| 2024incomplete | 42,514 | $2.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 66% | 54,451 | 50,905 | $9.35M |
| S9083 | Global fee urgent care centers | 31% | 38,116 | 30,562 | $4.36M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.2% | 34,590 | 31,902 | $176K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 10,768 | 10,444 | $106K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 9,944 | 9,361 | $72K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,018 | 1,005 | $38K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 1,798 | 1,742 | $34K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,024 | 7,372 | $18K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,318 | 3,095 | $8K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,780 | 2,711 | $7K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 5,425 | 4,913 | $5K |
| 0001A | <1% | 436 | 377 | $3K |
78 more codes
| 0011A | <1% | 179 | $1K | |
| 0002A | <1% | 267 | $880.00 | |
| 0031A | <1% | 95 | $640.00 | |
| 99443 | <1% | 742 | $636.70 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,009 | $519.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 490 | $314.46 |
| 81025 | <1% | 10,604 | $309.56 | |
| 0071A | <1% | 107 | $280.00 | |
| 96127 | <1% | 4,144 | $256.98 | |
| 0012A | <1% | 118 | $240.00 | |
| 86580 | <1% | 5,465 | $183.79 | |
| 99384 | <1% | 169 | $81.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,338 | $66.62 |
| 81002 | <1% | 1,607 | $42.81 | |
| 0064A | <1% | 14 | $40.00 | |
| 0052A | <1% | 26 | $40.00 | |
| 0072A | <1% | 34 | $40.00 | |
| 99499 | <1% | 174 | $40.00 | |
| 0004A | <1% | 30 | $40.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,328 | $38.80 |
| 3725F | <1% | 2,110 | $30.00 | |
| 81003 | <1% | 1,855 | $25.29 | |
| 90716 | <1% | 68 | $20.00 | |
| 90715 | <1% | 218 | $10.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 365 | $6.30 |
| 99401 | <1% | 364 | $1.08 | |
| 99201 | <1% | 120 | $0.07 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 491 | $0.03 |
| 99385 | <1% | 93 | $0.02 | |
| 91305 | 0% | 96 | $0.00 | |
| 99070 | 0% | 92 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 1,327 | $0.00 |
| 3351F | 0% | 1,850 | $0.00 | |
| 91301 | 0% | 225 | $0.00 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 381 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 49 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 1,288 | $0.00 |
| 59430 | 0% | 54 | $0.00 | |
| 91303 | 0% | 48 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 400 | $0.00 |
| 86592 | 0% | 320 | $0.00 | |
| 87088 | 0% | 12 | $0.00 | |
| 82607 | 0% | 13 | $0.00 | |
| 99000 | 0% | 384 | $0.00 | |
| 80051 | 0% | 24 | $0.00 | |
| 99429 | 0% | 49 | $0.00 | |
| 82746 | 0% | 13 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 29 | $0.00 |
| 81000 | 0% | 12 | $0.00 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 53 | $0.00 |
| 91307 | 0% | 74 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 25 | $0.00 |
| 0051A | 0% | 17 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 29 | $0.00 |
| 87490 | 0% | 14 | $0.00 | |
| 87590 | 0% | 14 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 20 | $0.00 |
| 91300 | 0% | 499 | $0.00 | |
| 99173 | 0% | 1,366 | $0.00 | |
| 87799 | 0% | 86 | $0.00 | |
| 80061 | Lipid panel | 0% | 45 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 727 | $0.00 |
| 87481 | 0% | 163 | $0.00 | |
| 90713 | 0% | 34 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 412 | $0.00 |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 0% | 78 | $0.00 |
| 82565 | 0% | 24 | $0.00 | |
| 87512 | 0% | 98 | $0.00 | |
| 90461 | 0% | 540 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 29 | $0.00 |
| 99442 | 0% | 52 | $0.00 | |
| G9357 | Post-partum screenings, evaluations and education performed | 0% | 49 | $0.00 |
| 90707 | 0% | 13 | $0.00 | |
| 82947 | 0% | 24 | $0.00 | |
| 84520 | 0% | 24 | $0.00 | |
| 90734 | 0% | 150 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 13 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPETRIKIN, TIMOTHY (SOLE MEMBER)